| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | ACRIGEN BIOSCIENCES, INC. | 626 BANCROFT WAY STE A | BERKELEY | CA | 94710-2262 | ALAMEDA | USA | R41TR003752 | Development of Safe in Utero Gene Editing Technology in Mice | 000 | 1 | NIH | 1/9/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | ACRIGEN BIOSCIENCES, INC. | 626 BANCROFT WAY STE A | BERKELEY | CA | 94710-2262 | ALAMEDA | USA | R43GM145002 | Enhancing CRISPR-mediated homology-directed repair using anti-CRISPR proteins | 000 | 1 | NIH | 4/28/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $256,580 ) |
| | 2022 | 2022 | ACRIGEN BIOSCIENCES, INC. | 202 STANFORD AVE | KENSINGTON | CA | 94708-1104 | ALAMEDA | USA | R43GM145002 | Enhancing CRISPR-mediated homology-directed repair using anti-CRISPR proteins | 000 | 1 | NIH | 2/15/2022 | $256,580 |
|
| Issue Date FY: 2021 ( Subtotal = $256,580 ) |
| | 2021 | 2021 | ACRIGEN BIOSCIENCES, INC. | 202 STANFORD AVE | KENSINGTON | CA | 94708-1104 | ALAMEDA | USA | R41TR003752 | Development of Safe in Utero Gene Editing Technology in Mice | 000 | 1 | NIH | 4/19/2021 | $256,580 |
| | 2021 | 2020 | ACRIGEN BIOSCIENCES, INC. | 202 STANFORD AVE | KENSINGTON | CA | 94708-1104 | ALAMEDA | USA | R43GM137621 | Discovery and applications of CRISPR-Cas inhibitor proteins | 000 | 1 | NIH | 6/26/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $252,131 ) |
| | 2020 | 2020 | ACRIGEN BIOSCIENCES, INC. | 202 STANFORD AVE | KENSINGTON | CA | 94708-1104 | ALAMEDA | USA | R43GM137621 | Discovery and applications of CRISPR-Cas inhibitor proteins | 000 | 1 | NIH | 4/2/2020 | $252,131 |
|
|
